Clinical Trial · NCT07019844

PSMA PET for the Staging and Management of Hepatocellular Carcinoma

Overview

This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT improves diagnostic accuracy for indeterminate liver lesions (LI-RADS 3 and 4), enhances staging precision in treatment-naïve patients, and provides more accurate assessment of treatment response in patients undergoing locoregional therapy (LRT). The goal is to assess how PSMA PET/CT may impact clinical decision-making, staging, and management of HCC across multiple stages of disease.

Sponsor

VA Office of Research and Development

Contacts

Binu V John, MD MPH (CONTACT)

binu.john@va.gov

(305) 575-7000

Binu V John, MD MPH (PRINCIPAL_INVESTIGATOR)

Flavia R Carneiro, PhD (CONTACT)

flavia.carneiro@va.gov

(305) 575-7762

ClinicalTrials.gov

NCT07019844

Eligibility

Inclusion

Treatment-naïve patients with HCC with BCLC B or C disease

Exclusion

Patients with renal dysfunction or contrast allergy that precludes contrast enhanced cross sectional imaging